Exit / M&A
Guided nuclear missile for cancer: Telix prepares for Nasdaq IPO
Telix, an ASX-listed radiopharmaceutical maker headquartered in Melbourne, is preparing a dual US listing; the piece also covers revenue growth, cancer trial results and recalls its 2017 float.